Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

NCT06642558 is registered in ClinicalTrials.gov with MAXVAX Biotechnology Limited Liability Company as lead sponsor.

NCT NCT06642558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06642558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 13, 2024
Completion date
February 28, 2027
Enrollment
522 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)